Loading clinical trials...

Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

NCT01776606•Revance Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This study will evaluate the efficacy and safety of botulinum toxin type A compared to placebo control for the treatment of moderate to severe crow's feet lines.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Moderate to severe crow's feet lines
•Female or male, 18 to 65 years of age and in good general health
•Women of childbearing potential (WOCBP) must agree to use an effective method of birth control during the course of the study

Exclusion Criteria

•Any neurological condition that may place the subject at increased risk with exposure to botulinum toxin type A
•Muscle weakness or paralysis, particularly in the area receiving study treatment
•Active skin disease or irritation at the treatment area
•Deep dermal scarring, or inability to smooth out the crow's feet lines to be treated by manually spreading the skin apart
•Treatment with botulinum toxin type A for crow's feet lines in the last 6 months

Locations (1)

Dermatology Research Institute

Coral Gables, Florida, United States

Key Dates

Start Date

December 1, 2012

Primary Completion Date

May 1, 2013

Completion Date

May 1, 2013

Last Updated

May 7, 2014

Enrollment

247

ACTUAL participants

Conditions

Skin Aging

Interventions

Botulinum Toxin Type A

DRUG

Placebo

DRUG

MENA Consensus on Poly-L-Lactic Acid (PLLA) Biostimulator Use in Aesthetic Dermatology

NCT07261748

Aesthetic ProceduresCosmetic Techniques+2 more

View study

ACTIVE_NOT_RECRUITINGNA

A Clinical Study to Evaluate the Efficacy of Activated Silk™ 27P-α in Subjects, Aged 35-65 Years of Age, to Improve the Signs of Aging

NCT06804759

Skin Aging

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 7, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

Inclusion Criteria

Exclusion Criteria

MENA Consensus on Poly-L-Lactic Acid (PLLA) Biostimulator Use in Aesthetic Dermatology

A Clinical Study to Evaluate the Efficacy of Activated Silk™ 27P-α in Subjects, Aged 35-65 Years of Age, to Improve the Signs of Aging

Efficacy and Safety of NP-2007 on Skin Health

A Pilot Study to Evaluate the Expanded Reach of Decentralized Digital Skin Health Clinical Studies

A Clinical Study Testing How Well the Medical Device HTIC (a Type of Animal-derived Collagen) Works in Treating Skin Problems, Such as Scars, Loss of Firmness, and Volume in Certain Areas of the Face and Body

Efficacy Study of Oral Collagen Peptide on Skin Condition Improvement